These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38342726)

  • 1. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
    Pepeler MS; Tıglıoglu M; Dagdas S; Ozhamamcıoglu E; Han U; Albayrak A; Aydın MS; Korkmaz G; Pamukcuoğlu M; Ceran F; Albayrak M; Ozet G
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e161-e167. PubMed ID: 38342726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia.
    Eliacik E; Isik A; Aydin C; Uner A; Aksu S; Sayinalp N; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Haznedaroglu IC
    Hematology; 2015 Aug; 20(7):392-6. PubMed ID: 25517484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
    Hidalgo-Lόpez JE; Kanagal-Shamanna R; Quesada AE; Gong Z; Wang W; Hu S; Medeiros LJ; Bassett RL; d'Orcy E; Yin CC; Cortes J; Jabbour EJ; Kantarjian HM; Bueso-Ramos CE
    Cancer; 2018 Oct; 124(19):3849-3855. PubMed ID: 30321462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
    Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
    Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
    Straetmans N; Ma DD; Nevell DF; Arthur C
    Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
    Lee MH; Song A; Li JY
    Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
    Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
    Tanrikulu Simsek E; Eskazan AE; Cengiz M; Ar MC; Ekizoglu S; Salihoglu A; Gulturk E; Elverdi T; Ongoren Aydin S; Senem Demiroz A; Buyru AN; Baslar Z; Ozbek U; Ferhanoglu B; Aydin Y; Tuzuner N; Soysal T
    J Clin Pathol; 2016 Sep; 69(9):810-6. PubMed ID: 26811428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
    Liu YL; Wang XN; Liu HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Ni J; Hong J; Zhang Z; Li Q; Xia R; Zeng Q; Sun G
    Leuk Lymphoma; 2020 May; 61(5):1195-1200. PubMed ID: 31858854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
    El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
    J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J; Hu J; Jin Z; Wan H
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Rios MB; Shan J; Cortes J
    Leuk Lymphoma; 2005 Jul; 46(7):993-7. PubMed ID: 16019549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis in Patients of Chronic Myeloid Leukemia in Chronic Phase at Presentation.
    Hamid A; Ashraf S; Qamar S; Naveed MA; Hameed A; Farooq MA
    J Coll Physicians Surg Pak; 2019 Nov; 29(11):1096-1100. PubMed ID: 31659970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.